Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans
- PMID: 9374685
- DOI: 10.1152/ajpendo.1997.273.5.E981
Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans
Abstract
Glucagon-like peptide 1 (GLP-1) has been shown to inhibit gastric emptying of liquid meals in type 2 diabetic patients. It was the aim of the present study to compare the action of physiological and pharmacological doses of intravenous GLP-1-(7-36) amide and GLP-1-(7-37) on gastric emptying in normal volunteers. Nine healthy subjects participated (26 +/- 3 yr; body mass index 22.9 +/- 1.6 kg/m2; hemoglobin A1C 5.0 +/- 0.2%) in five experiments on separate occasions after an overnight fast. A nasogastric tube was positioned for the determination of gastric volume by use of a dye-dilution technique (phenol red). GLP-1-(7-36) amide (0.4, 0.8, or 1.2 pmol.kg-1.min-1), GLP-1-(7-37) (1.2 pmol.kg-1.min-1), or placebo was infused intravenously from -30 to 240 min. A liquid meal (50 g sucrose, 8% amino acids, 440 ml, 327 kcal) was administered at 0 min. Glucose, insulin, and C-peptide were measured over 240 min. Gastric emptying was dose dependently slowed by GLP-1-(7-36) amide (P < 0.0001). Effects of GLP-1-(7-37) at 1.2 pmol.kg-1.min-1 were virtually identical. GLP.1 dose dependently stimulated fasting insulin secretion (-30 to 0 min) and slightly reduced glucose concentrations. After the meal (0-240 min), integrated incremental glucose (P < 0.0001) and insulin responses (P = 0.01) were reduced (dose dependently) rather than enhanced. In conclusion, 1) GLP-1-(7-36) amide or -(7-37) inhibits gastric emptying also in normal subjects, 2) physiological doses (0.4 pmol.kg-1.min-1) still have a significant effect, 3) despite the known insulinotropic actions of GLP-1-(7-36) amide and -(7-37), the net effect of administering GLP-1 with a meal is no change or a reduction in meal-related insulin responses. These findings suggest a primarily inhibitory function for GLP-1 (ileal brake mechanisms).
Similar articles
-
Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.Diabetes. 2005 Jul;54(7):2212-8. doi: 10.2337/diabetes.54.7.2212. Diabetes. 2005. PMID: 15983224
-
Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.J Clin Endocrinol Metab. 1996 Jan;81(1):327-32. doi: 10.1210/jcem.81.1.8550773. J Clin Endocrinol Metab. 1996. PMID: 8550773 Clinical Trial.
-
Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.Diabetologia. 1996 Dec;39(12):1546-53. doi: 10.1007/s001250050613. Diabetologia. 1996. PMID: 8960841 Clinical Trial.
-
Is glucagon-like peptide 1 an incretin hormone?Diabetologia. 1999 Mar;42(3):373-9. doi: 10.1007/s001250051165. Diabetologia. 1999. PMID: 10096792 Review.
-
Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective.Acta Diabetol. 1998 Oct;35(3):117-29. doi: 10.1007/s005920050116. Acta Diabetol. 1998. PMID: 9840447 Review.
Cited by
-
Gastrointestinal safety evaluation of semaglutide for the treatment of type 2 diabetes mellitus: A meta-analysis.Medicine (Baltimore). 2024 May 24;103(21):e38236. doi: 10.1097/MD.0000000000038236. Medicine (Baltimore). 2024. PMID: 38787986 Free PMC article.
-
The Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Does Not Increase the Risk of Pancreatic Cancer: A U.S.-Based Cohort Study.Cancers (Basel). 2024 Apr 23;16(9):1625. doi: 10.3390/cancers16091625. Cancers (Basel). 2024. PMID: 38730578 Free PMC article.
-
Transforming Diabetes Care: The Molecular Pathways through Which GLP1-RAs Impact the Kidneys in Diabetic Kidney Disease.Biomedicines. 2024 Mar 14;12(3):657. doi: 10.3390/biomedicines12030657. Biomedicines. 2024. PMID: 38540270 Free PMC article. Review.
-
Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression.Curr Opin Nephrol Hypertens. 2024 May 1;33(3):331-336. doi: 10.1097/MNH.0000000000000976. Epub 2024 Feb 23. Curr Opin Nephrol Hypertens. 2024. PMID: 38411162 Review.
-
Dietary Fibre for the Prevention of Post-Pancreatitis Diabetes Mellitus: A Review of the Literature and Future Research Directions.Nutrients. 2024 Feb 1;16(3):435. doi: 10.3390/nu16030435. Nutrients. 2024. PMID: 38337719 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous